As Filed with the Securities and Exchange Commission on August 5, 2005

Registration No. 333-88042

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM S-3

VALEANT PHARMACEUTICALS INTERNATIONAL

(Exact Name of Registrant as Specified in its Charter)

Delaware (State or Other Jurisdiction of Incorporation or Organization)		33-0628076 (I.R.S. Employer Identification Number)

3300 Hyland Avenue
Costa Mesa, CA 92626
(714) 545-0100
(Address, including Zip Code, and Telephone Number, including Area Code,
of Registrant’s Principal Executive Offices)

Eileen C. Pruette
Executive Vice President, General Counsel
Valeant Pharmaceuticals International
3300 Hyland Avenue
Costa Mesa, CA 92626
(714) 545-0100
(Name, Address, including Zip Code, and Telephone Number, including Area Code,
of Agent for Service)

Approximate date of commencement of proposed sale to public: Not applicable.

     If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. o

     If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. o

     If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

     If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o

     If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. o

 

 

DEREGISTRATION OF SECURITIES

On May 10, 2002, Valeant Pharmaceuticals International, then named ICN Pharmaceuticals, Inc., a Delaware corporation (the “Registrant”), filed a registration statement on Form S-3 (SEC File No. 333-88042) (as amended by Amendment No. 1 filed on August 16, 2002) (the “Registration Statement”) to register for resale by selling security holders identified in the Registration Statement of up to 565,010 shares of the Registrant’s common stock.

The Registration Statement was declared effective on August 16, 2002 and was to remain effective until the earliest of (a) the date when all of the shares registered by the Registration Statement have been distributed to the public, (b) the date that the selling security holders are each eligible to sell all of their shares offered under the prospectus included in the Registration Statement in any three-month period pursuant to Rule 144 under the Securities Act of 1933 and (c) May10, 2003 (such earliest date being the date of termination of the offering). In accordance with an undertaking in the Registration Statement, the Registrant hereby files this Post-Effective Amendment No. 1 to remove from registration all securities, if any, under the Registration Statement which remained unsold at the termination of the offering.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Costa Mesa, State of California, on August 3, 2005.

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature		Title		Date
/s/ Timothy C. Tyson   Timothy C. Tyson		President, Chief Executive Officer and Director Officer (Principal Executive Officer)		August 3, 2005
/s/ Bary G. Bailey   Bary G. Bailey		Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)		August 3, 2005
/s/ Robert W. O’Leary   Robert W. O’Leary		Chairman of the Board		August 3, 2005
/s/ Randy H. Thurman   Randy H. Thurman		Director		August 3, 2005
/s/ Edward A. Burkhardt   Edward A. Burkhardt		Director		August 3, 2005
/s/ Robert A. Ingram   Robert A. Ingram		Director		August 3, 2005
/s/ Richard H. Koppes   Richard H. Koppes		Director		August 3, 2005
/s/ Lawrence N. Kugelman   Lawrence N. Kugelman		Director		August 3, 2005
/s/ Theo Melas-Kyriazi   Theo Melas-Kyriazi		Director		August 3, 2005
/s/ Elaine Ullian   Elaine Ullian		Director		August 3, 2005